People

People

Robert Flavell, MD, PhD

Principal Investigator, Associate Professor Division Chief, Molecular Imaging & Therapeutics

Robert Flavell, MD, PhD, is the Chief of Molecular Imaging and Therapeutics Clinical Section in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He received his medical degree from Weill Cornell Medical College, and his PhD from the Rockefeller University as part of the Tri-Institutional MD PhD program. He completed his one-year internship at the Memorial Sloan­Kettering Cancer Center in New York. Dr.

Megha Basak, PhD, MSc

Postdoctoral Fellow

Dr. Megha Baska is a chemist and preclinical research scientist dedicated to developing tumor-selective therapeutics that will improve outcomes for patients with metastatic and drug-resistant cancers. Her research focuses on the rational design, synthesis, and optimization of targeted drug delivery systems—including small molecules, nanopolymers, and antibody-based platforms. She has developed novel linker chemistries and delivery strategies to enhance tumor-specific targeting, improve therapeutic efficacy, and increase tumor-to-background ratios while minimizing off-target toxicity.

Changhua Mu, PhD

Assistant Researcher

  • Assistant Professional Researcher – Molecular Imaging and Therapy
    Department of Radiology and Biomedical Imaging, University of California-San Francisco, United States
  • Postdoctoral Scholar (II) – Molecular Imaging and Therapy
    Department of Radiology and Biomedical Imaging, University of California-San Francisco, United States
  • Postdoctoral scholar (I) – Molecular and Cellular Biophotonics
    Department of Bioengineering, University of California-Berkeley, United States
  • Ph.D. – Inorganic Therapeutics and Magnetic Resonance Spectroscopy

Athira Raveendran, PhD

Postdoctoral Fellow

Dr. Athira Raveendran is a Postdoctoral Fellow in the Department of Radiology and Biomedical Imaging. At UCSF, Dr. Raveendran focuses on the development and evaluation of novel radioimmunoconjugates for cancer imaging and therapy. Her research integrates molecular design with translational imaging approaches to advance precision oncology. She has extensive experience in coordinating and leading preclinical studies, with a particular emphasis on antibodies and peptide-based radiopharmaceuticals for prostate and bladder cancers.

David Wilson, MD, PhD

Professor, Associate Director Clinical Scientists T32 Training Program, Lead of Chemistry, Probes, and Molecular Therapy (CPMT)